Mesenchymal tumors make up only about 1% of primary GI tumors, with Gastrointestinal Stromal Tumors (GIST) being the most common nonepithelial GI neoplasms. They are derived from the Interstitial cells of Cajal (ICC), and occur predominantly in older individuals, with a mean age of diagnosis of 64 years. Here we discuss the case of a 39-year-old female with atypical thoracic back pain wrapping around to the front and migrating diffuse abdomen pain that sometimes radiates into the chest. Upon imaging, a gastric GIST of the greater curve of the stomach was found incidentally on investigation of a pancreatic mass that was revealed to be a co-occurring pancreatic neuroendocrine tumor. For management of the gastric GIST and pancreatic neuroendocrine tumor, this patient underwent partial gastrectomy with gastrojejunostomy, partial pancreatectomy, splenectomy, and cholecystectomy with no complications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063710 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2021.03.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diffuse expression of p16 in pancreatic neuroendocrine tumors (PanNETs) and the association of morphology variants.
Am J Clin Pathol
January 2025
Department of Pathology, Duke University Medical Center, Durham, NC, US.
Objective: Distinguishing grade 3 pancreatic neuroendocrine tumors (PanNETs) from neuroendocrine carcinomas (PanNECs) is sometimes challenging. Recently, a diffuse p16-positive pattern was reported in PanNECs but not in grade 3 PanNETs, suggesting that p16 could help differentiate these entities. This study aimed to investigate p16 expression in PanNETs of various grades and its association with clinicopathologic features.
View Article and Find Full Text PDFmiR-223 and Chromogranin A Affect Inflammatory Immune Cell Activation in Liver Metastasis of Neuroendocrine Neoplasms.
Cells
January 2025
Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Neuroendocrine neoplasms (NENs) are a diverse group originating from endocrine cells/their precursors in pancreas, small intestine, or lung. The key serum marker is chromogranin A (CgA). While commonly elevated in patients with NEN, its prognostic value is still under discussion.
View Article and Find Full Text PDFCan CT Image Reconstruction Parameters Impact the Predictive Value of Radiomics Features in Grading Pancreatic Neuroendocrine Neoplasms?
Bioengineering (Basel)
January 2025
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
The WHO grading of pancreatic neuroendocrine neoplasms (PanNENs) is essential in patient management and an independent prognostic factor for patient survival. Radiomics features from CE-CT images hold promise for the outcome and tumor grade prediction. However, variations in reconstruction parameters can impact the predictive value of radiomics.
View Article and Find Full Text PDFDeep Learning Enabled Scoring of Pancreatic Neuroendocrine Tumors Based on Cancer Infiltration Patterns.
Endocr Pathol
January 2025
Department of Computer Engineering, Koc University, Istanbul, Turkey.
Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms that include tumors with different histomorphologic characteristics that can be correlated to sub-categories with different prognoses. In addition to the WHO grading scheme based on tumor proliferative activity, a new parameter based on the scoring of infiltration patterns at the interface of tumor and non-neoplastic parenchyma (tumor-NNP interface) has recently been proposed for PanNET categorization. Despite the known correlations, these categorizations can still be problematic due to the need for human judgment, which may involve intra- and inter-observer variability.
View Article and Find Full Text PDFCase report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy.
Front Oncol
January 2025
Department of Nuclear Medicine, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United States.
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!